Adagrasib 200 mg Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 200 mg
Reference Brands: Krazati (USA)
Category: Oncology Cancer Care
Adagrasib is a small-molecule inhibitor that selectively binds to the mutant KRAS G12C protein, preventing cancer cell growth and survival. It is primarily used in certain non-small cell lung cancers (NSCLC) and colorectal cancers with the KRAS G12C mutation.
Adagrasib — third party manufacturing & bulk supply
Adagrasib 200 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Adagrasib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Adagrasib →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Adagrasib is used to treat certain cancers in adult patients whose tumors carry the KRAS G12C mutation. It is approved for advanced or metastatic Non‑Small Cell Lung Cancer (NSCLC) after prior therapy, and in combination with Cetuximab for advanced or metastatic Colorectal Cancer (CRC) with KRAS G12C mutation in patients who have received prior chemotherapy.
Adagrasib is a small‑molecule drug designed to irreversibly bind to the mutant KRAS G12C protein, inhibiting its function and blocking tumor-promoting signaling. Its chemical formula is C₃₂H₃₅ClFN₇O₂, and it is formulated with excipients suitable for oral administration.
The trade name for Adagrasib is Krazati.
Adagrasib (Krazati) was developed by Mirati Therapeutics and is part of Bristol Myers Squibb’s oncology portfolio. Generic production is not widely available yet.
The generic name is adagrasib.
The brand name is Krazati.
Adagrasib is manufactured under GMP conditions in regulated facilities operated by Mirati Therapeutics and Bristol Myers Squibb for global distribution.a
Related Products
Fruquin 5 Mg (Fruquintinib)
Strength:
5 Mg
Form: Capsules
Reference Brands: Everest Bangladesh altd.
View Details
Vorinostat
Strength:
100 mg
Form: Capsules
Reference Brands: Zolinza (USA/EU), Vornat (India)
View Details
Panobinostat Lactate
Strength:
10 mg, 15 mg, 20 mg
Form: Capsules
Reference Brands: Farydak (USA/EU),
View Details
Gilteritinib
Strength:
40 mg
Form: Tablets
Reference Brands: Xospata (USA/India), LuciGil (Asia)
View DetailsQuick Response Guaranteed | Verified Suppliers
